340 related articles for article (PubMed ID: 31595333)
1. ΔNp63 transcript loss in bladder cancer constitutes an independent molecular predictor of TaT1 patients post-treatment relapse and progression.
Papadimitriou MA; Avgeris M; Levis PK; Tokas T; Stravodimos K; Scorilas A
J Cancer Res Clin Oncol; 2019 Dec; 145(12):3075-3087. PubMed ID: 31595333
[TBL] [Abstract][Full Text] [Related]
2. Unraveling UCA1 lncRNA prognostic utility in urothelial bladder cancer.
Avgeris M; Tsilimantou A; Levis PK; Rampias T; Papadimitriou MA; Panoutsopoulou K; Stravodimos K; Scorilas A
Carcinogenesis; 2019 Aug; 40(8):965-974. PubMed ID: 30815670
[TBL] [Abstract][Full Text] [Related]
3. Loss of GAS5 tumour suppressor lncRNA: an independent molecular cancer biomarker for short-term relapse and progression in bladder cancer patients.
Avgeris M; Tsilimantou A; Levis PK; Tokas T; Sideris DC; Stravodimos K; Ardavanis A; Scorilas A
Br J Cancer; 2018 Dec; 119(12):1477-1486. PubMed ID: 30374124
[TBL] [Abstract][Full Text] [Related]
4. Ki-67 is an independent indicator in non-muscle invasive bladder cancer (NMIBC); combination of EORTC risk scores and Ki-67 expression could improve the risk stratification of NMIBC.
Ding W; Gou Y; Sun C; Xia G; Wang H; Chen Z; Tan J; Xu K; Qiang D
Urol Oncol; 2014 Jan; 32(1):42.e13-9. PubMed ID: 24360660
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Implication of Urothelial Stem Cell Markers Differs According to Primary Tumour Location in Non-Muscle-Invasive Bladder Cancer.
Wang L; Zhao J; Yang C; Kuang R; Kazobinka G; Pang Z; Hou T
Cell Physiol Biochem; 2018; 48(6):2364-2373. PubMed ID: 30114689
[TBL] [Abstract][Full Text] [Related]
6. Ras association domain family 1A: a promising prognostic marker in recurrent nonmuscle invasive bladder cancer.
Kim JS; Chae Y; Ha YS; Kim IY; Byun SS; Yun SJ; Kim WJ
Clin Genitourin Cancer; 2012 Jun; 10(2):114-20. PubMed ID: 22382007
[TBL] [Abstract][Full Text] [Related]
7. miR-221/222 cluster expression improves clinical stratification of non-muscle invasive bladder cancer (TaT1) patients' risk for short-term relapse and progression.
Tsikrika FD; Avgeris M; Levis PK; Tokas T; Stravodimos K; Scorilas A
Genes Chromosomes Cancer; 2018 Mar; 57(3):150-161. PubMed ID: 29181884
[TBL] [Abstract][Full Text] [Related]
8. ΔNp63 expression is a protective factor of progression in clinical high grade T1 bladder cancer.
Gaya JM; López-Martínez JM; Karni-Schmidt O; Bonal DM; Algaba F; Palou J; Villavicencio H; Benson MC; Cordon-Cardo C; Castillo-Martin M
J Urol; 2015 Apr; 193(4):1144-50. PubMed ID: 25444981
[TBL] [Abstract][Full Text] [Related]
9. Cell-cycle markers do not improve discrimination of EORTC and CUETO risk models in predicting recurrence and progression of non-muscle-invasive high-grade bladder cancer.
Passoni N; Gayed B; Kapur P; Sagalowsky AI; Shariat SF; Lotan Y
Urol Oncol; 2016 Nov; 34(11):485.e7-485.e14. PubMed ID: 27637323
[TBL] [Abstract][Full Text] [Related]
10. Snail is an independent prognostic indicator for predicting recurrence and progression in non-muscle-invasive bladder cancer.
Gou Y; Ding W; Xu K; Wang H; Chen Z; Tan J; Xia G; Ding Q
Int Urol Nephrol; 2015 Feb; 47(2):289-93. PubMed ID: 25388353
[TBL] [Abstract][Full Text] [Related]
11. Can re-cTURBT be useful in pT1HG disease as a risk indicator of recurrence and progression? A single centre experience.
Giulianelli R; Gentile BC; Mirabile G; Albanesi L; Tariciotti P; Rizzo G; Buscarini M; Vermiglio M
Arch Ital Urol Androl; 2017 Dec; 89(4):272-276. PubMed ID: 29473376
[TBL] [Abstract][Full Text] [Related]
12. Urotensin II receptor determines prognosis of bladder cancer regulating cell motility/invasion.
Franco R; Zappavigna S; Gigantino V; Luce A; Cantile M; Cerrone M; Facchini G; Perdonà S; Pignata S; Di Lorenzo G; Chieffi S; Vitale G; De Sio M; Sgambato A; Botti G; Yousif AM; Novellino E; Grieco P; Caraglia M
J Exp Clin Cancer Res; 2014 Jun; 33(1):48. PubMed ID: 24893613
[TBL] [Abstract][Full Text] [Related]
13. STAG2 as a prognostic biomarker in low-grade non-muscle invasive bladder cancer.
Taber A; Park Y; Lelo A; Prip F; Xiao J; Berry DL; Chaldekas K; Jensen JB; Philips G; Kim JS; Harris BT; Dyrskjøt L; Waldman T
Urol Oncol; 2021 Jul; 39(7):438.e1-438.e9. PubMed ID: 33712344
[TBL] [Abstract][Full Text] [Related]
14. Calgranulin A (S100A8) Immunostaining: A Future Candidate for Risk Assessment in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC).
Nicklas AP; Kramer MW; Serth J; Hennenlotter J; Hupe MC; Reimer DU; Stenzl A; Merseburger AS; Kuczyk MA; von Klot CJ
Adv Ther; 2018 Nov; 35(11):2054-2068. PubMed ID: 30232708
[TBL] [Abstract][Full Text] [Related]
15. Distinct expression profiles of p63 variants during urothelial development and bladder cancer progression.
Karni-Schmidt O; Castillo-Martin M; Shen TH; Gladoun N; Domingo-Domenech J; Sanchez-Carbayo M; Li Y; Lowe S; Prives C; Cordon-Cardo C
Am J Pathol; 2011 Mar; 178(3):1350-60. PubMed ID: 21356385
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of protocadherin 8 (PCDH8) promoter methylation in non-muscle invasive bladder cancer.
Lin YL; Wang YL; Ma JG; Li WP
J Exp Clin Cancer Res; 2014 Aug; 33(1):68. PubMed ID: 25927589
[TBL] [Abstract][Full Text] [Related]
17. Prognostic Value of BUB1 for Predicting Non-Muscle-Invasive Bladder Cancer Progression.
Piao XM; You C; Byun YJ; Kang HW; Noh J; Lee J; Lee HY; Kim K; Kim WT; Yun SJ; Lee SC; Kang K; Kim YJ
Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884561
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of α‑ and β‑Klotho in urothelial carcinoma of the bladder.
Hori S; Miyake M; Onishi S; Tatsumi Y; Morizawa Y; Nakai Y; Anai S; Tanaka N; Fujimoto K
Oncol Rep; 2016 Oct; 36(4):2117-25. PubMed ID: 27573985
[TBL] [Abstract][Full Text] [Related]
19. HMOX1 is an important prognostic indicator of nonmuscle invasive bladder cancer recurrence and progression.
Yim MS; Ha YS; Kim IY; Yun SJ; Choi YH; Kim WJ
J Urol; 2011 Feb; 185(2):701-5. PubMed ID: 21168882
[TBL] [Abstract][Full Text] [Related]
20. Tumor expression of miR-34a-3p is an independent predictor of recurrence in non-muscle-invasive bladder cancer and promising additional factor to improve predictive value of EORTC nomogram.
Juracek J; Stanik M; Vesela P; Radova L; Dolezel J; Svoboda M; Slaby O
Urol Oncol; 2019 Mar; 37(3):184.e1-184.e7. PubMed ID: 30446443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
